Does dietary choline, phosphatidylcholine, and carnitine produce TMAO and raise cardiometabolic risk?

TMAO (trimethylamine N-oxide) links dietary nutrient metabolism, the gut microbiome, hepatic oxidation, and renal clearance. The claim is well supported: choline/phosphatidylcholine and carnitine can generate circulating TMAO through a microbiota-dependent pathway, and higher TMAO concentrations consistently predict less favorable cardiovascular outcomes.

Human mechanistic evidence

• Stable-isotope feeding studies show that labeled phosphatidylcholine produces labeled TMAO in plasma and urine. Antibiotic suppression of intestinal microbes nearly abolished this response, with recovery after antibiotics were withdrawn.
• Labeled carnitine likewise produces labeled TMAO; microbial suppression markedly reduces formation and recolonization restores it. Four weeks of red-meat intake increased plasma and urinary TMAO by more than twofold versus white-meat or non-meat diets in controlled feeding research.
• The pathway is: dietary choline/phosphatidylcholine or carnitine → microbial trimethylamine (TMA); for carnitine, γ-butyrobetaine is an identified intermediate → hepatic flavin-containing monooxygenase oxidation of TMA to TMAO. Magnitude varies substantially by diet and individual microbial metabolic capacity.

Cardiometabolic associations

• Prospective meta-analyses associate higher TMAO with cardiovascular events (HR 1.23), major adverse cardiovascular/cerebrovascular events (HR 1.67), all-cause mortality (HR 1.55–1.91), and an estimated 7.6% higher mortality per 10-μmol/L increase.
• These are prognostic associations, not proof that TMAO itself is an independent cause of disease. Reduced kidney function raises TMAO through diminished renal clearance and independently raises cardiovascular risk; diet, metabolic illness, fasting status, and reverse causation also affect interpretation.

Clinical implications

• TMAO should not supplant established cardiovascular risk assessment or kidney-function evaluation. Assay- and population-dependent thresholds limit interpretation, and TMAO-guided treatment or TMAO-lowering interventions have not been shown to improve outcomes.

Bottom line

• Dietary choline/phosphatidylcholine and carnitine are established microbiota-dependent precursors of TMAO, and elevated circulating TMAO is a robust marker of higher future cardiovascular and mortality risk, though not a proven stand-alone causal treatment target.